Nalbuphine hydrochloride - Generic Drug Details

What are the generic sources for nalbuphine hydrochloride and what is the scope of patent protection?

Nalbuphine hydrochloride is the generic ingredient in three branded drugs marketed by Abbvie, Abraxis Pharm, Abbott, Dr Reddys, Hospira, Igi Labs Inc, Rising, Somerset Theraps Llc, and Ph Health, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for nalbuphine hydrochloride. Six suppliers are listed for this compound.

Summary for nalbuphine hydrochloride

US Patents:	0
Tradenames:	3
Applicants:	9
NDAs:	20
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	163
Patent Applications:	1,059
What excipients (inactive ingredients) are in nalbuphine hydrochloride?	nalbuphine hydrochloride excipients list
DailyMed Link:	nalbuphine hydrochloride at DailyMed

Recent Clinical Trials for nalbuphine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CMH Lahore Medical College and Institute of Dentistry	NA
Liaquat National Hospital & Medical College	PHASE1
Zhongshan Ophthalmic Center, Sun Yat-sen University	PHASE4

See all nalbuphine hydrochloride clinical trials

Pharmacology for nalbuphine hydrochloride

Drug Class	Opioid Agonist/Antagonist
Mechanism of Action	Competitive Opioid Antagonists Partial Opioid Agonists

Medical Subject Heading (MeSH) Categories for nalbuphine hydrochloride

Analgesics, Opioid

Narcotic Antagonists

Narcotics

Anatomical Therapeutic Chemical (ATC) Classes for nalbuphine hydrochloride

N02AF	Morphinan derivatives
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

US Patents and Regulatory Information for nalbuphine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	NALBUPHINE HYDROCHLORIDE	nalbuphine hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	207595-001	Jan 11, 2019		DISCN	No	No
Igi Labs Inc	NALBUPHINE HYDROCHLORIDE	nalbuphine hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	072074-001	Apr 10, 1989		DISCN	No	No
Ph Health	NUBAIN	nalbuphine hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	018024-005	Mar 2, 1984		DISCN	Yes	No
Dr Reddys	NALBUPHINE HYDROCHLORIDE	nalbuphine hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	074471-002	Mar 19, 1998		DISCN	No	No

Nalbuphine hydrochloride Market Analysis and Financial Projection

Last updated: February 13, 2026

What are the market dynamics for nalbuphine hydrochloride?

Nalbuphine hydrochloride is an opioid analgesic used primarily for pain management. It functions as a mixed kappa opioid receptor agonist and mu opioid receptor antagonist, providing analgesia with reduced risk of respiratory depression compared to full mu-opioid agonists.

Market Drivers

• Growing opioid analgesic demand: Rise in surgical procedures and chronic pain management increases need for effective analgesics like nalbuphine.
• Shift towards safer opioids: Preference for agents associated with less respiratory depression drives interest, especially in institutional settings.
• Regulatory environment: Tighter controls on traditional opioids propel pharmaceutical development of safer alternatives.
• Generic entry: Several generic versions available, pressuring branded pricing but expanding access.

Market Challenges

• Regulatory hurdles: Classification as a controlled substance restricts manufacturing, distribution, and prescribing.
• Limited patent protection: Loss of exclusivity across key markets results in price erosion.
• Market saturation: Existence of established opioids reduces incremental demand for nalbuphine.
• Stigma and misuse concerns: Ongoing opioid misuse concerns could limit prescribing.

Market Size and Growth

• As of 2022, the global opioid analgesics market was valued at approximately USD 13 billion; nalbuphine represents a small portion, estimated at below USD 200 million.
• Compound annual growth rate (CAGR): Nearly 3% projected from 2022-2027, driven mainly by developed markets adopting safer opioid options.

Competitive Landscape

• Major players: Pfizer, Mundipharma, and Contract Manufacturing Organizations (CMOs) producing generic formulations.
• Product pipeline: Limited, with no substantial new formulations or indications announced recently.
• Pricing trends: Generics dominate, prices declining due to increased competition and market saturation.

What is the financial trajectory for nalbuphine hydrochloride?

Revenue Trends

• Revenues remain modest, with manufacturers primarily relying on existing generic markets.
• Key branded formulations have faced revenue declines as patent protections expire.
• Contract manufacturing has become an increasingly important revenue stream for companies with production capacity.

Cost Structure

• Manufacturing costs: Moderate, with economies of scale in generic production.
• Regulatory compliance: Significant investment in maintaining drug approval status.
• Marketing and distribution: Limited for generics; higher for branded formulations.

Profitability

• Margins are pressured by price erosion in generics.
• High initial R&D investments are offset by limited revenue potential, leading to low or negative returns on investment for new entrants.

Investment Outlook

• The outlook remains cautious; traditional growth drivers are plateauing.
• Patent expirations further dampen revenue prospects.
• Investment in next-generation formulations or new indications is unlikely in the near term.

How do regulatory policies influence market and financial prospects?

• Controlled substance regulation: Class II drug status in the US restricts manufacturing, prescribing, and distribution.
• Generic approval pathways: Streamlined due to established manufacturing processes, reducing entry barriers for generics.
• Orphan drug or new formulation incentives: Unlikely, as nalbuphine does not qualify for these programs.
• Post-market surveillance: Mandatory reporting heightens compliance costs but deters unsafe use.

What's the competitive outlook?

• Limited innovation results in stable but stagnant markets.
• Market entry barriers are significant due to regulatory controls.
• Competition mainly from generics and alternative opioids like hydromorphone and oxycodone.

Key Takeaways

• Nalbuphine hydrochloride's market remains small, driven by safety considerations and existing generic competition.
• Revenue potential is constrained by patent expirations and market saturation.
• Regulatory controls restrict manufacturing and prescribing, complicating market expansion.
• Investment prospects are limited unless innovative formulations or new indications emerge.
• Competitive landscape is primarily composed of generic providers with little recent pipeline development.

FAQs

Q1: Are there new formulations of nalbuphine hydrochloride in development?
No, there are no publicly announced new formulations or indications under development.

Q2: How does nalbuphine compare to other opioid analgesics in terms of safety?
It has a lower risk of respiratory depression and dependence compared to full mu-opioid agonists, making it preferable in certain settings.

Q3: What are the main regulatory concerns impacting nalbuphine?
Its status as a controlled substance creates restrictions on manufacturing, prescribing, and distribution.

Q4: How do patent expirations affect the market?
Patents have expired in major markets, leading to increased generic competition and price declines.

Q5: What factors could lead to increased demand for nalbuphine?
Potentially, if regulations favor safer opioids or new pain management protocols emerge that prioritize opioid alternatives with improved safety profiles.

---

References

1. Market data from IBISWorld, 2022.
2. FDA Drug Approvals and Controlled Substance Schedule, 2022.
3. Industry analyst reports, 2023.